About this event
Rare diseases are receiving sharper focus as the scale of the challenge facing the NHS comes to light.
Event Details:
In this FREE 60-minute Live NHS Update, our qualified panel of NHS experts will discuss the potential decisions and tactics that the industry needs to look out for.
“Although rare diseases may be individually rare, they are collectively common, with 1 in 17 people being affected by a rare disease at some point in their lives.” UK Rare Diseases Framework (2021)
Rare diseases are receiving sharper focus as the scale of the challenge facing the NHS comes to light. As the world of Integrated Care Systems (ICSs) turns its priorities towards rare diseases, it opens up many opportunities for the Life Science Industry, including collaborative working and best practice sharing.
Key Learning Objectives:
- How will the NHS interpret the changes relating to ICSs?
- What impact will this have on Life Sciences?
- Where will decisions be made about formularies?
- How will these decisions be implemented?
- What are some of the likely tactical measures that the NHS may deploy on national, regional or local levels?
To see our other events, go to our website: https://lsaccessacademy.com/Events
Hosted by
-
Guest speaker
Henry Burkitt Oxygen Strategy @ FounderG
Henry is the founder of Oxygen - a strategic healthcare public affairs company based in the new diplomatic precinct of Nine Elms in London.
-
Team member
Ian Chamberlain Managing Director @ Life Science Access AcademyT
Ian co-founded the Life Science Access Academy with Nigel Robbins to bring together all the best ideas in people development from more than 20 innovative specialist consultancies.
-
Guest speaker
Steven Ferguson Director of Strategic Market Access (UK & I) @ IQVIAG
Steve heads up IQVIAs Market Access function and brings extensive Industry experience, having worked across a number of pharmaceutical companies, most recently at Merck where he led on Market Access across their broad portfolio.
-
Guest speaker
David Ashford Jones Owner & Lead Consultant @ Sagio LtdG
David combines personal patient experience and deep knowledge of pharma.
-
Guest speaker
Andrew Mumford CEO @ Initiate.G
Andrew is a highly experienced Global Market Access expert, leading pragmatic, solution focussed consultancy services at Initiate, a best-in-class consultancy with exceptional experience in the rare disease sector. Having gained initial experience in field-based and market-access commercial roles, his career moved into senior management roles leading HTA submissions, pricing and reimbursement projects, Value Dossier development, and Value Communication across global markets. Andrew has a unique set of experience, developing and implementing access initiatives with a particular focus on launching new products in the rare disorder arena. His focus is primarily to ensure clinical demand, value demonstration, and acceptance by the payer customer group independent of their market, data set, and belief.
-
Guest speaker
Neil Grubert Global Market Access ExpertG
Neil is a pharmaceutical market access specialist with more than 20 years of experience tracking access environments around the world. He advises leading biopharmaceutical companies on the implications of international access trends and has authored more than 150 reports on the subject. Neil also delivers multi-client and bespoke training programmes.
Life Science Access Academy Ltd
LSAA is a truly Global Membership Community for all staff from across the Life Science sector including: commercial, clinical and financial sales teams, medics and support teams.
